ARVN(Arvinas, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $53.60M | $131.40M | $78.50M | $263.40M | $262.60M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | −$188.40M | −$263.20M | −$401.50M | −$250.20M | −$118.50M |
| 净利润 | −$191.00M | −$282.50M | −$367.30M | −$198.90M | −$80.80M |
| 经营现金流 | $559.40M | −$273.50M | −$347.80M | −$259.30M | −$273.80M |
| 自由现金流 | $554.70M | −$280.30M | −$350.70M | −$261.10M | −$275.70M |
| 摊薄每股收益 | $-3.82 | $-5.31 | $-6.62 | $-2.77 | $-1.14 |